| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cardiff Oncology, Inc.$1.33
+0.01 (+0.76%)
D 30Pipeline Score Richly Valued Biotech · Commercial
Market Cap
121.70 M
EPS
-0.67
P/E Ratio
-
Value Trade
3.53 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
41.00 K
R&D Expenses
6.76 M
Operating CF
-12.29 M
Total Assets
49.17 M
Total Liabilities
14.46 M
Equity
34.71 M
D/E Ratio
12,345
7.88 %
Week
5.95 %
1 Month
9.2 %
3 Month
-9.18 %
6 Month
-78.68 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
46.06 M
Monthly Burn
4.10 M
Runway
9.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
801.89 K
52 Week Range
1.48 - 4.56
% held by Insiders
8.54 %
% held by Institutions
29.92 %
Enterprise Value
76.29 M
Total Shares
68.34 M
Short %
25.82 %
Float Shares
64.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardiff Oncology, Inc.
578Total events
1Upcoming
86Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 1
Event history 577
Jun 4, 2026
◆Oral PresentationPresentation
Cardiff Oncology management to present at Jefferies Global Healthcare Conference
Jun 3, 2026
◆Quarterly UpdateOnvansertibApprovedCorporate
Investor webcast to review updated CRDF-004 data
first-line RAS-mutated metastatic colorectal cancersource ↗
Jun 3, 2026
◆Quarterly UpdateCorporate
Investor webcast to review Phase 2 data and registrational study plans
Jun 2, 2026
◆Oral PresentationOnvansertibApprovedPresentation
Rapid oral presentation of updated Phase 2 data of onvansertib in first-line RAS-mutated mCRC at ASCO 2026
first-line RAS-mutated metastatic colorectal cancer (mCRC)source ↗
Jun 2, 2026
▲End Of Phase 2 MeetingOnvansertibApprovedFDA Meeting
Successful End-of-Phase 2 meeting with FDA; alignment on registrational trial design
first-line RAS-mutated metastatic colorectal cancersource ↗
May 29, 2026
◆Oral PresentationOnvansertibApprovedPresentation
Rapid oral presentation of updated CRDF-004 data at ASCO 2026
first-line RAS-mutated metastatic colorectal cancersource ↗
May 21, 2026
◆AbstractOnvansertibApprovedPresentation
Abstract for CRDF-004 trial available on ASCO website
first-line RAS-mutated metastatic colorectal cancer (mCRC)source ↗
Apr 30, 2026
◆Oral PresentationOnvansertibApprovedPresentation
KOL webinar discussing onvansertib single-agent activity in CMML
chronic myelomonocytic leukemia (CMML)source ↗
Apr 19, 2026
◆Poster PresentationOnvansertibApprovedPresentation
Poster presentation of preclinical data on onvansertib + T-DXd at AACR 2026
HER2-low breast cancersource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $9M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 35%
Micro Cap (rank 593 of 911)
Percentile RankCardiff Oncology, Inc. faces pipeline headwinds (30/100), with $164M risk-adjusted pipeline value, led by Onvansertib in Metastatic Colorectal Cancer (Phase 2), across $63B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onvansertib Small molecule | Small-cell Lung Cancer | Phase 2 | NCT05450965 | 19% | $154M | RECRUITING | 37 | - | - | Nov 30, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
onvansertib | first-line RAS-mutated mCRC | Phase 2 | 2026-06-02 | overall response rate: 72.2%; standard of care response rate: 42.1%; improvement: 30%; PFS hazard ratio: 0.55; PFS CI: 95% CI: 0.15–2.09 Read More | Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting Read More | |
onvansertib | first-line RAS-mutated mCRC | Phase 2 | 2026-06-02 | overall response rate: 72.2%; standard of care response rate: 42.1%; improvement: 30%; PFS hazard ratio: 0.55; PFS CI: 95% CI: 0.15–2.09 Read More | Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting Read More | |
onvansertib | first-line RAS-mutated mCRC | Phase 2 | 2026-06-02 | overall response rate: 72.2%; standard of care response rate: 42.1%; improvement: 30%; PFS hazard ratio: 0.55; PFS CI: 95% CI: 0.15–2.09 Read More | Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRDF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRDF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRDFCardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Cardiff Oncology announced positive results from its Phase 2 trial of onvansertib in RAS-mutated mCRC, showing a 72.2% overall response rate compared to 42.1% for standard-of-care. The trial confirmed the safety and efficacy of the 30 mg dose combined with FOLFIRI/bevacizumab. A registrational Phase 3 trial is planned following FDA alignment.
Read more →CRDFCardiff Oncology to Participate in the Jefferies Global Healthcare Conference 2026
Cardiff Oncology, a clinical-stage biotechnology firm, will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Mani Mohindru will lead a fireside chat on June 4, discussing their lead asset, onvansertib, which targets PLK1 inhibition in cancer treatment. The company aims to address significant unmet needs in RAS-mutated metastatic colorectal cancer.
Read more →CRDF▼ -22.1%on this newsshared move
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Cardiff Oncology, Inc. will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Mani Mohindru will participate in a fireside chat on June 4, discussing the company's innovative cancer therapies, particularly their lead asset, onvansertib. This drug is currently in a Phase 2 trial for treating RAS-mutated metastatic colorectal cancer.
Read more →CRDFCardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology announced an investor webcast on June 3, 2026, to discuss updated Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. The data will first be presented at the ASCO Annual Meeting on June 2, 2026. This follows earlier findings indicating onvansertib's effectiveness in improving patient outcomes when combined with standard treatments.
Read more →CRDFCardiff Oncology Reports First Quarter 2026 Results and Provides Business Update Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial C
Cardiff Oncology announced its first quarter 2026 results, highlighting a successful End-of-Phase 2 meeting with the FDA regarding the Phase 3 trial design for onvansertib in treating first-line RAS-mutated metastatic colorectal cancer (mCRC). The company reported encouraging outcomes from its Phase 2 CRDF-004 trial, including a high objective response rate and improved progression-free survival. Cardiff is set to present additional data at the upcoming ASCO Annual Meeting, while the company also appointed new executive leadership to support its growth strategy. Financially, Cardiff maintains a robust cash position, enabling operations into early 2027.
Read more →CRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 28, 2026
Cardiff Oncology has granted non-qualified stock options to Dr. Aggarwal as part of his induction as Chief Operating Officer. The grant, totaling 400,000 shares, complies with Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $1.72 per share. The options will vest over four years, contingent on Dr. Aggarwal's continued employment.
Read more →CRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology has granted non-qualified stock options to Dr. Aggarwal, its new COO, as an inducement for his employment. The grant includes 400,000 shares with an exercise price of $1.72 per share. This option vests over four years, reflecting the company's commitment to attract top talent while advancing its cancer treatment initiatives, particularly with its lead asset, onvansertib.
Read more →CRDFCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Cardiff Oncology will host a key opinion leader webinar on April 30, 2026, to discuss the promising single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML). The webinar will feature KOL Mrinal Patnaik from Mayo Clinic, who specializes in hematology and precision genomics. This event aims to share insights from an investigator-initiated trial and enhance understanding of onvansertib's clinical potential.
Read more →CRDF▼ -7.3%on this news
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib at the ASCO 2026 Annual Meeting. The trial evaluates onvansertib in combination with standard care for first-line RAS-mutated metastatic colorectal cancer. This presentation underscores the company's commitment to addressing significant unmet needs in cancer treatment.
Read more →CRDF▲ +6.5%on this newsshared move
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Cardiff Oncology, Inc. presented promising preclinical data at the 2026 AACR Annual Meeting regarding their PLK1 inhibitor, onvansertib, in combination with the HER2-targeted antibody-drug conjugate, trastuzumab deruxtecan (T-DXd). This combination displayed strong antitumor activity and showed potential in overcoming resistance in HER2-low breast cancer models. Key findings included significant tumor regression rates and enhanced survival, indicating a new treatment avenue for patients resistant to current therapies. The company continues to advance onvansertib through various clinical evaluations across multiple cancer types.
Read more →CRDF▼ -5.4%on this news
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Cardiff Oncology has appointed Mani Mohindru as President and CEO, following her interim role. The company also welcomed Josh Muntner as CFO and Ajay Aggarwal as COO. These appointments aim to enhance leadership as Cardiff advances its lead asset, onvansertib, in treating RAS-mutant metastatic colorectal cancer. The new team is expected to drive the company's strategic priorities forward.
Read more →CRDFCardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology will host a key opinion leader webinar on March 25, 2026, focusing on first-line RAS-mutated metastatic colorectal cancer. The webinar will feature experts Scott Kopetz and Heinz-Josef Lenz discussing the clinical data of onvansertib, a PLK1 inhibitor. This event aims to shed light on emerging treatment strategies for this patient population.
Read more →CRDFCardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Cardiff Oncology announced the upcoming presentation of preclinical data on its oral PLK1 inhibitor, onvansertib, at the AACR Annual Meeting 2026. The research highlights onvansertib's ability to enhance the effectiveness of trastuzumab deruxtecan in HER2-low breast cancer models. This presentation underscores the drug's potential in overcoming therapy resistance and its role in various cancers including RAS-mutated colorectal cancer. The findings will be available on the company's website following the event.
Read more →CRDFCardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology, Inc. (CRDF) announced participation in three investor conferences scheduled for March 2026. These include the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference 2026. The company is known for its focus on PLK1 inhibition as a strategy to develop novel therapies for various cancers, highlighting its lead asset, onvansertib, currently evaluated in a Phase 2 trial. Interested parties can access conference webcasts via the Cardiff Oncology website.
Read more →CRDF▲ +12.4%on this newsshared move
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology reported positive results from its Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer, showing a 72.2% overall response rate. The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data expected in the first half of 2026. Financially, Cardiff has a strong cash position to support operations into 2027.
Read more →CRDF▲ +12.4%on this newsshared move
FEBRUARY 2026 Company Overview The Onvansertib Opportunity Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995
The presentation discusses the opportunities and challenges related to Onvansertib, a selective PLK1 inhibitor targeting RAS-mutant metastatic colorectal cancer (mCRC). It highlights promising clinical trial results, including a 72% overall response rate in trials, and outlines plans for a registrational program with potential FDA accelerated approval. Despite the optimistic outlook, the company acknowledges significant risks associated with clinical trial outcomes, regulatory approvals, and competition in the oncology landscape.
Read more →CRDFCardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Cardiff Oncology, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. The presentation will be delivered by Dr. Mani Mohindru, the Interim CEO. Cardiff is focusing on PLK1 inhibition to develop therapies for various cancers, particularly its lead asset, onvansertib, which is being evaluated in a Phase 2 trial for RAS-mutated metastatic colorectal cancer. This event highlights the company's ongoing commitment to addressing significant patient needs within oncology.
Read more →CRDF▼ -32%on this news· ran to -45% by day 1
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Cardiff Oncology announced positive results from its Phase 2 trial of onvansertib in combination with FOLFIRI/bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer. The trial demonstrated significant improvements in overall response rates and progression-free survival. The company plans to initiate a registrational program later this year, targeting the 30 mg dose of onvansertib. The treatment was well-tolerated with no major toxicities reported.
Read more →CRDF▼ -32%on this news· ran to -45% by day 1shared move
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Cardiff Oncology has announced a leadership transition to support its late-stage clinical development. Dr. Mani Mohindru has been appointed as the interim CEO following the departure of Mark Erlander and James Levine. The company aims to advance its lead product candidate, onvansertib, which is currently in mid-stage trials for RAS-mutated metastatic colorectal cancer. The transition reflects the company's focus on execution and clinical advancement as it prepares for key milestones.
Read more →CRDF▲ +10.9%on this news
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Cardiff Oncology has presented clinical data from an investigator-sponsored trial of onvansertib in chronic myelomonocytic leukemia (CMML) at the ASH Annual Meeting. The Phase 1 trial indicated that onvansertib was well-tolerated and showed preliminary efficacy in about 40% of patients. Nevertheless, Cardiff does not intend to pursue further development of onvansertib for CMML, despite the drug's validated activity in hematologic and solid tumors. The findings contribute to the growing body of research on onvansertib, which is also being tested in other cancer indications.
Read more →CRDF▲ +10.9%on this news
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Cardiff Oncology, Inc. (NASDAQ: CRDF) announced its participation in Sidoti’s Year-End Virtual Investor Conference scheduled for December 10-11, 2025. CEO Mark Erlander will present and host one-on-one meetings, providing investors with insights into the company's developments. Cardiff Oncology focuses on PLK1 inhibition to develop therapies for various cancers, including RAS-mutated metastatic colorectal cancer and small cell lung cancer. Interested parties can access the live webcast and its replay through the company’s website.
Read more →CRDFCardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
Cardiff Oncology, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. CEO Mark Erlander will lead a fireside chat on December 2 at 9:30 AM ET. The company focuses on developing therapies targeting various cancers through PLK1 inhibition, with ongoing clinical programs for several indications.
Read more →CRDFCardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Cardiff Oncology reported positive results from its Phase 2 CRDF-004 trial, which evaluates onvansertib combined with standard care for RAS-mutated metastatic colorectal cancer. The trial demonstrated a 19% improvement in overall response rate and better progression-free survival metrics. The company has sufficient cash reserves to fund operations into Q1 2027, with further updates expected in early 2026.
Read more →CRDFCardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology, Inc. (Nasdaq: CRDF) will participate in two investor conferences in November 2025. CEO Mark Erlander will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference and the Stifel 2025 Healthcare Conference. These events will include fireside chats and corporate presentations, enhancing the company's outreach to investors.
Read more →CRDF▼ -24.8%on this news
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
Cardiff Oncology announced promising results from its Phase 2 trial of onvansertib for RAS-mutated mCRC. The trial showed a 49% confirmed objective response rate (ORR) in the 30mg dose arm compared to 30% in the control group. Early data also suggest improved progression-free survival (PFS) outcomes. The treatment was well-tolerated, with no major toxicities reported.
Read more →CRDF▼ -11.3%on this news· ran to -33% by day 1shared move
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - Appointed Dr. Roger Sidhu as Chief Medical Officer – - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvan
Cardiff Oncology (CRDF) reported its second quarter 2025 results, announcing significant milestones such as the appointment of Dr. Roger Sidhu as Chief Medical Officer and the completion of patient enrollment in the Phase 2 CRDF-004 trial for onvansertib. The company shared positive results from an investigator-initiated trial in metastatic triple negative breast cancer and disclosed financial stability with $71 million in cash, projected to sustain operations into Q1 2027. A conference call is scheduled to discuss updated clinical data and the ongoing progress of their trials.
Read more →CRDF▼ -18.4%on this news
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology has appointed Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar. Dr. Sidhu brings over 20 years of oncology experience and will lead the clinical program for onvansertib. The company plans to share additional clinical data from the CRDF-004 trial for RAS-mutated mCRC on July 29, 2025.
Read more →CRDFCardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
Cardiff Oncology announced positive results from a Phase 1b trial of onvansertib combined with paclitaxel for metastatic triple-negative breast cancer. The trial showed a 40% objective response rate, particularly at the highest dose of onvansertib. The combination therapy was well-tolerated, indicating a favorable safety profile. These findings support the potential of onvansertib in treating this aggressive cancer subtype.
Read more →CRDF▲ +5.6%on this news
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-m
Cardiff Oncology, Inc. has announced its Q1 2025 results, highlighting the completion of enrollment in the randomized Phase 2 CRDF-004 trial for treating first-line RAS-mutated metastatic colorectal cancer (mCRC). The company also secured a second patent extending its intellectual property rights for onvansertib treatment across various mCRC treatment paradigms. As of March 31, 2025, Cardiff reported liquidity of approximately $79.9 million, expected to sustain operations until Q1 2027. Despite these advances, the company noted an increase in operating costs and cash burn compared to the previous year.
Read more →CRDFCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
Cardiff Oncology has received a second patent for onvansertib, covering its use in treating bevacizumab-naïve metastatic colorectal cancer (mCRC) patients. This patent, issued by the USPTO, enhances the company's intellectual property and broadens the applicability of onvansertib across various lines of therapy. The company is currently conducting a Phase 2 trial evaluating onvansertib in combination with standard treatments for mCRC patients.
Read more →CRDF▲ +5.4%on this news
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology has completed patient enrollment in its Phase 2 CRDF-004 trial evaluating onvansertib for first-line treatment of RAS-mutated metastatic colorectal cancer. The milestone marks progress in developing new therapies for a patient population lacking recent treatment advancements. The company plans to report additional clinical data in the first half of 2025, which could influence further regulatory discussions with the FDA. The trial includes a randomized assessment of onvansertib combined with standard treatments against standard care alone.
Read more →CRDF▼ -9%on this news
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (&#
Cardiff Oncology announced its fourth quarter and full year 2024 results, highlighting a robust efficacy signal for onvansertib in the ongoing first-line RAS-mut mCRC trial. The treatment showed a 64% response rate in patients receiving 30mg of onvansertib, compared to 33% in the control arm. Additionally, the company raised $40 million in an oversubscribed offering and secured a new patent for its drug. With approximately $91.7 million in cash reserves projected to support operations into 2027, Cardiff plans to provide further updates on the clinical trial in the first half of 2025.
Read more →CRDFCardiff Oncology to Present at Upcoming Investor Conferences
Cardiff Oncology, Inc. (Nasdaq: CRDF) has announced that its management will participate in two upcoming investor conferences. CEO Mark Erlander will present at the B. Riley Securities Precision Oncology & Radiopharma Conference and the TD Cowen 45th Annual Health Care Conference. These presentations will provide insight into the company's development strategies and focus on improving responses in cancers like colorectal cancer. Cardiff Oncology aims to leverage PLK1 inhibition to develop novel therapies across various cancer indications.
Read more →CRDFCardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced that it will hold a conference call on February 27, 2025, to review its financial results for the fourth quarter of 2024. The company is focused on developing novel therapies targeting PLK1 inhibition for various cancer types, including metastatic colorectal cancer and pancreatic cancer. The conference call will be accessible via a webcast on their investor website, ensuring transparency with stakeholders.
Read more →CRDF▲ +54.9%on this news
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Cardiff Oncology announced positive initial data from the Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard-of-care for first-line RAS-mutated mCRC. The trial showed a 64% objective response rate in patients receiving the 30mg dose of onvansertib, significantly higher than the 33% ORR in the control arm. Onvansertib was found to be well tolerated across both dosage arms. The company anticipates providing additional clinical data in the first half of 2025.
Read more →CRDF▲ +54.9%on this news
DECEMBER 10, 2024 CRDF-004 Trial 1st Line RAS-mutated mCRC Initial Data Release Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigati
The CRDF-004 trial is investigating the efficacy of Onvansertib in treating first-line RAS-mutated metastatic colorectal cancer (mCRC). Initial dataset shows that response rates for patients receiving Onvansertib in combination with standard chemotherapy (SoC) are encouraging, outpacing control arms. The study aims to evaluate the safety and effectiveness of this treatment approach, although outcomes remain uncertain due to inherent risks in clinical trials and potential regulatory approval challenges.
Read more →CRDF▲ +54.9%on this news
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Cardiff Oncology has announced the pricing of an oversubscribed underwritten direct offering of 15,384,619 shares at $2.60 each, expected to generate approximately $40 million in gross proceeds. The funds will be allocated to support clinical trials for the company's lead asset, onvansertib, particularly in first-line treatment for RAS-mutated metastatic colorectal cancer. The transaction is anticipated to close on December 11, 2024, subject to customary closing conditions. This financing highlights strong investor confidence and the potential for significant advancements in Cardiff's oncology programs.
Read more →CRDFCardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Cardiff Oncology has announced the issuance of a new patent from the USPTO for onvansertib, which covers its use in combination with bevacizumab for treating KRAS mutated metastatic colorectal cancer (mCRC) patients. Expected to expire in 2043, this patent supports Cardiff's strategy to advance onvansertib as a first-line treatment option. The company is currently conducting a Phase 2 trial to evaluate onvansertib alongside standard therapies, with initial results expected by the end of 2024. This announcement marks a significant milestone in Cardiff's development of innovative cancer therapies.
Read more →CRDF▲ +7.3%on this news· ran to -19% by day 1
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update - Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-r
Cardiff Oncology reported its third quarter 2024 financial results, highlighting positive Phase 2 trial outcomes for onvansertib in combination with FOLFIRI and bev in second-line KRAS-mutant metastatic colorectal cancer (mCRC). The trial results, published in the Journal of Clinical Oncology, demonstrated that the treatment was well-tolerated and resulted in a significantly higher clinical benefit for bev naive patients. The company anticipates an initial data readout from the ongoing first-line RAS-mutated mCRC trial, CRDF-004, by the end of 2024. Overall, Cardiff's financial position is sound, with sufficient cash resources to continue operations into Q1 2026.
Read more →CRDFCardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Cardiff Oncology announced the publication of data from its Phase 2 trial evaluating onvansertib in combination with FOLFIRI and bevacizumab for second-line KRAS-mutant metastatic colorectal cancer (mCRC). The results showed a significant clinical benefit, especially in treatment-naïve patients, with a 77% objective response rate. Given this success, the company plans to advance onvansertib's development to first-line RAS-mutant mCRC, with preliminary results from the ongoing CRDF-004 trial expected in late 2024. The findings have been published in the Journal of Clinical Oncology.
Read more →CRDFCardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
Cardiff Oncology has reported its financial results for the second quarter of 2024, revealing a focus on the CRDF-004 trial for first-line RAS-mutated mCRC. The company remains optimistic about their lead candidate, onvansertib, particularly its potential to change treatment paradigms. Recent preclinical data indicates its effectiveness against PARP-resistant ovarian cancer. Although the company's cash reserves are substantial, they have noted an increase in operating expenses associated with clinical activities, which may impact financial stability moving forward.
Read more →CRDFCardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
Cardiff Oncology, a clinical-stage biotechnology company, announced it will release its financial results for the second quarter of 2024 on August 8, following market close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Cardiff is focusing on leveraging PLK1 inhibition to develop therapies for multiple cancers, including metastatic colorectal cancer and triple negative breast cancer.
Read more →CRDFCardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology, Inc. will present at the upcoming Jefferies Healthcare Conference held in New York on June 5-6, 2024. Company CEO Mark Erlander is scheduled to speak from 8:30 to 8:55 AM ET. Their main focus is on leveraging PLK1 inhibition to develop new therapies for multiple cancers, including metastatic colorectal and pancreatic cancers. Interested investors can participate through live webcasts available on their website, further showcasing the company's engagement with stakeholders.
Read more →CRDFCardiff Oncology to Present at Upcoming Investor Conferences in May
Cardiff Oncology, Inc. (CRDF) has announced that its management will present at two upcoming investor conferences in May 2024. The presentations, featuring CEO Mark Erlander, will take place at the H.C. Wainwright BioConnect Investor Conference in New York City and the Cowen Oncology Innovation Summit. These events highlight Cardiff's commitment to advancing its portfolio of cancer therapies leveraging PLK1 inhibition.
Read more →CRDF▲ +5.9%on this news· ran to -22% by day 3
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Cardiff Oncology reported positive first-quarter results for 2024, highlighting the efficacy of onvansertib in treating RAS-mutated metastatic colorectal cancer (mCRC). Key data from the ONSEMBLE trial and AACR presentations showcase the drug's effectiveness, potentially revolutionizing treatments in a market without new approvals for over two decades. Moreover, the company maintains a solid financial position with $67 million in cash, projected to sustain operations through Q3 2025. An important interim data readout is anticipated in the second half of 2024, marking a potential inflection point for the firm.
Read more →CRDFCardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Cardiff Oncology, Inc. (Nasdaq: CRDF) has announced its plans to release financial results for the first quarter ending March 31, 2024, on May 2. Following the results announcement, the company will host a conference call and live webcast, allowing investors to engage with its management. The company is focused on leveraging PLK1 inhibition to develop therapies aimed at treating various types of cancers, including mCRC and mPDAC.
Read more →CRDFCardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Cardiff Oncology presented novel preclinical data on its lead asset, onvansertib, at the AACR Annual Meeting 2024. The data showcased onvansertib's ability to inhibit tumor vascularization and growth in RAS-mutated metastatic colorectal cancer (mCRC), demonstrating a significant increase in overall clinical response rates, particularly in bevacizumab-naïve patients. Additionally, the findings support ongoing clinical trials evaluating the drug in combination with standard treatments across various cancer types, indicating its potential broad applicability. Overall, the presentation reinforces Cardiff's strategy for onvansertib in treating mCRC and other indications.
Read more →CRDF▲ +6.6%on this news
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Cardiff Oncology, Inc. announced that it will present five abstracts at the AACR Annual Meeting 2024. These presentations will cover the potential of its PLK1 inhibitor, onvansertib, in treating various cancers, including KRAS-mutant colorectal cancer. The company reported strong clinical results from its trials and discussed the mechanism of action of onvansertib in combination with bevacizumab. Additional data regarding onvansertib's activity in treating small cell lung cancer and ovarian cancer will also be shared.
Read more →CRDFCardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Cardiff Oncology reported its fourth quarter and full year 2023 results, highlighting significant progress in its clinical trials. The company has dosed the first patient in a Phase 2 trial for RAS-mutated metastatic colorectal cancer and anticipates interim data by mid-2024. Financially, Cardiff Oncology has $75 million in cash, providing a robust runway into Q3 2025, despite increases in operating expenses. The announcement emphasizes the potential of their lead drug candidate, onvansertib, amidst the backdrop of no new therapies approved in this indication over the past two decades.
Read more →CRDFCardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Cardiff Oncology has provided an update on the ONSEMBLE trial for RAS-mutated metastatic colorectal cancer, reporting data from a trial that has now been discontinued to focus on first-line therapies. The Phase 2 ONSEMBLE trial, which included 23 patients, demonstrated efficacy for onvansertib in combination with FOLFIRI and bevacizumab. The trial's discontinuation was influenced by FDA recommendations and the company's objective to allocate resources more efficiently. Cardiff anticipates sharing topline results from its new first-line therapy program in mid-2024.
Read more →CRDFCardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Cardiff Oncology announced the dosing of the first patient in its Phase 2 trial (CRDF-004) evaluating onvansertib in patients with RAS-mutated metastatic colorectal cancer. Conducted in partnership with Pfizer Ignite, the trial aims to assess onvansertib's safety and efficacy when added to standard-of-care treatments. The trial will include up to 90 patients and generate initial topline results expected by mid-2024. Positive prior trial results encourage the belief that this treatment could be a significant advancement for mCRC patients.
Read more →CRDFCardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
Cardiff Oncology, Inc. (Nasdaq: CRDF) will participate in the Cowen 44th Annual Health Care Conference from March 4-6, 2024, in Boston. The CEO, Mark Erlander, will present in a fireside chat scheduled for 1:30 PM ET. The company focuses on developing novel therapies targeting various cancers using PLK1 inhibition. Interested parties can access the live webcasts through the Cardiff Oncology website, which will also offer replay options after the presentations.
Read more →CRDFCardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced plans to release its financial results for the fourth quarter and full year ended December 31, 2023, on February 29, 2024. Following the announcement, a conference call and live webcast will be held to discuss these results. The company is focused on developing therapies for cancers leveraging its lead asset, onvansertib, which targets PLK1 inhibition. Various clinical programs, including those for metastatic colorectal cancer and pancreatic cancer, reflect its commitment to addressing unmet medical needs.
Read more →CRDF▼ -8.2%on this news· ran to +27% by day 1
AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan PFIZER We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 mCRC clinical development program agreed with FDA • Ȃ
AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan PFIZER We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 mCRC clinical development program agreed with FDA • • • • • • 5 3 Annual eligible U
Read more →CRDFDocument Cardiff Oncology Announces Proposed Public Offering SAN DIEGO (
Cardiff Oncology Announces Proposed Public Offering SAN DIEGO (September 29, 2020) - Cardiff Oncology, Inc. (Nasdaq CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mu
Read more →CRDFCardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC) SAN DIEGO (May 13, 2020) - Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs
Read more →CRDFTrovagene Announces $5.0 Million Private Placement Priced At-the-Market SAN DIEGO (
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market SAN DIEGO (October 25, 2019) Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment
Read more →CRDFTrovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2 Phase 1b dose escalation clinical trial confirmed safety, prelimi
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2 Phase 1b dose escalation clinical trial confirmed safety, preliminary efficacy and identified the recommended phase 2 dose o
Read more →CRDFTrovagene to Present at the H.C.
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference SAN DIEGO (September 3, 2019) - Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeutics company developing drugs that target cell division (mitosis) for
Read more →CRDFTrovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) SAN DIEGO (August 26, 2019) - Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeutics company
Read more →CRDFTrovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference SAN DIEGO, CA August 15, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeut
Read more →CRDFTrovagene Announces Second Quarter 2019 Results and Highlights
Trovagene Announces Second Quarter 2019 Results and Highlights SAN DIEGO, CA August 8, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage Precision Cancer Medicine company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and soli
Read more →CRDFESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation Acute Myeloid Leukemia (AML) clinical trial data to be presented in an oral presentation Metatstatic Colorectal Cancer (mCRC) clinical trial data a
ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation Acute Myeloid Leukemia (AML) clinical trial data to be presented in an oral presentation Metatstatic Colorectal Cancer (mCRC) clinical trial data and triple-negative breast cancer (TNBC) preclinical data t
Read more →CRDFTrovagene Commences Non-Deal Investor Roadshow Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvans
Trovagene Commences Non-Deal Investor Roadshow Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvansertib SAN DIEGO, CA July 15, 2019 Trovagene, Inc. (Nasdaq:
Read more →CRDFTrovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin (bevacizumab) for treatment of patients with KRAS-
Read more →CRDFTrovagene Company Update Conference Call Script Friday
Trovagene Company Update Conference Call Script Friday, June 7, 2019 - 11:00 a.m. EDT (8:00 a.m. PDT) Speaker dial-in: (877) 330-2645; Conference ID: 8596214 Debrief with LHA immediately after the call: 877-852-2556; Passcode: 3106917104 Welcome to the Trovagene conference
Read more →CRDFTrovagene to Host Business Update Conference Call on
Trovagene to Host Business Update Conference Call on June 7, 2019 Conference Call Begins at 11:00 am EDT SAN DIEGO, CA May 30, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target
Read more →CRDFTrovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD in Models of Colorectal Cancer ONZEALD is currently being evaluated in a Phase 3 tria
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD in Models of Colorectal Cancer ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metas
Read more →CRDFTrovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital Additional funding further extends runway for Trovagene to accelerate clinical developmen
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital Additional funding further extends runway for Trovagene to accelerate clinical development of onvansertib for the treatment of cancers where new th
Read more →CRDFTrovagene Announces First Quarter 2019 Results and Highlights
Trovagene Announces First Quarter 2019 Results and Highlights SAN DIEGO, CA May 7, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of l
Read more →CRDFTrovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML Data provides support for clinical evaluation of onvanserib in combinatio
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML Data provides support for clinical evaluation of onvanserib in combination with venetoclax in patients with difficult-to-treat relap
Read more →CRDFTrovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants Fun
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants Funding in place to help advance onvansertib three clinical d
Read more →CRDFEarly Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy Early PSA response observed when onvansertib is added to abiraterone (Zytiga
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy Early PSA response observed when onvansertib is added to abiraterone (Zytiga ) in 2 of 6 patients to-date; first patient achieves prim
Read more →CRDFPhase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels Greatest anti-leukemic activity has been
Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with compl
Read more →CRDFTrovagene Receives Approximately $3.0 Million From Exercise of Warrants
Trovagene Receives Approximately $3.0 Million From Exercise of Warrants SAN DIEGO, CA March 13, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the
Read more →CRDFTrovagene Regains Compliance with Nasdaq Listing Requirements
Trovagene Regains Compliance with Nasdaq Listing Requirements SAN DIEGO, CA March 12, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment
Read more →CRDFTrovagene Announces Fourth Quarter and Full-Year 2018 Results
Trovagene Announces Fourth Quarter and Full-Year 2018 Results SAN DIEGO, CA March 6, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment o
Read more →CRDFTrovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting
Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting SAN DIEGO, CA February 28, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precisio
Read more →CRDFTrovagene, Inc. Announces Reverse Stock Split Reverse stock split intended to bring company into compliance with minimum bid price requirement for maintaining listing on Nasdaq Capital Market
Trovagene, Inc. Announces Reverse Stock Split Reverse stock split intended to bring company into compliance with minimum bid price requirement for maintaining listing on Nasdaq Capital Market SAN DIEGO, CA February 19, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage onco
Read more →CRDFTrovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerate
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated Expanding trial to include alternate dosing schedule to
Read more →CRDFTrovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC) Trovagene receives may proceed notification from FDA for Phase 1b/2 trial of Onvansertib in com
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer Trovagene receives may proceed notification from FDA for Phase 1b/2 trial of Onvansertib in combination with standard-of-care in patients with mCRC harboring KRA
Read more →CRDFTrovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer Broad patent covers anti-androgen or androgen antagonist drugs, includi
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer Broad patent covers anti-androgen or androgen antagonist drugs, including combination treatment with Zytiga , Xtandi and Erleada
Read more →CRDFTrovagene Announces Adjournment of Special Meeting of Stockholders Until
Trovagene Announces Adjournment of Special Meeting of Stockholders Until February 12, 2019 SAN DIEGO, CA January 15, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cel
Read more →CRDFNew Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML - Preliminary Anti-Leukemic Activity Demonstrates 80% Response to Treatme
New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML - Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabi
Read more →CRDFTrovagene, Inc. Receives Positive Nasdaq Listing Decision
Trovagene, Inc. Receives Positive Nasdaq Listing Decision SAN DIEGO, CA November 15, 2018 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the tre
Read more →CRDFTrovagene Announces Launch of New Company Website New website offers visitors greater insight into the Company s focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical pro
Trovagene Announces Launch of New Company Website New website offers visitors greater insight into the Company s focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical program SAN DIEGO, CA November 13, 2018 Trovagene, Inc. (NAS
Read more →CRDFTrovagene Announces Third Quarter 2018 Highlights and Financial Results
Trovagene Announces Third Quarter 2018 Highlights and Financial Results SAN DIEGO, CA November 7, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for th
Read more →CRDFTrovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting Targeted treatment with highly-selective, oral Polo-like Kinase 1 (P
Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard
Read more →CRDFLicensed Drug Candidate from NMS Onvansertib - Polo-like Kinase 1 (PLK1) Inhibitor Largest oncology research and development company in Italy Developed anthracycline class of drugs (doxorubicin) Leader in protein kinase
Company Update Wednesday, October 24th, Licensed Drug Candidate from NMS Onvansertib - Polo-like Kinase 1 (PLK1) Inhibitor Largest oncology research and development company in Italy Developed anthracycline class of drugs (doxorubicin) Leader in protein kinase drug development (
Read more →CRDFTrovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday
Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018 -Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT SAN DIEGO, CA October 18, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-s
Read more →CRDFTrovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer Patent agreement covers rights to develop combination therapies and id
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer type
Read more →CRDFTrovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose lev
Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine i
Read more →CRDFTrovagene Announces Participation at The MicroCap Conference on October 1 st and 2 nd at the Essex House in New York City Company overview, update on Onvansertib clinical development program and anticipated near-term val
Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones SAN DIEGO, CA September 18, 2018 Tr
Read more →CRDFTrovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib Target engagement and inhibition of PLK1 by Onvansertib predictive of tre
Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response SAN DIEGO, CA September 05, 2018 Trovagen
Read more →CRDFTrovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe SAN DIEGO, CA August 29, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision med
Read more →CRDFTrovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of O
Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC)
Read more →CRDFTrovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3 rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 Onvansertib s product profile and attributes may offer the potential to p
Trovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 Onvansertib s product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy
Read more →CRDFTrovagene Announces Second Quarter 2018 Highlights and Financial Results
Trovagene Announces Second Quarter 2018 Highlights and Financial Results SAN DIEGO, CA August 3, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias, lymphomas and solid tumor cance
Read more →CRDFTrovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene s Investigational Cancer Drug
Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene s Investigational Cancer Drug SAN DIEGO, CA August 1, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeut
Read more →CRDFForward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words su
Using Our Precision Medicine Strategy to Develop Oncology Drugs That Target Mitosis July 2018 Exhibit 99.1 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These s
Read more →CRDFTrovagene Presents Outlook for Second Half of 2018
Trovagene Presents Outlook for Second Half of 2018 DIEGO, July 9, 2018 /PRNewswire/ Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today provided an updat
Read more →CRDFTrovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML Additional
Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML Additional pharmacodynamic data supports inhibition of PLK1 in leuk
Read more →CRDFTrovagene Announces Leadership Change William Welch has resigned as CEO and Director Dr. Thomas Adams, Chairman of the Board Appointed Interim
Trovagene Announces Leadership Change William Welch has resigned as CEO and Director Dr. Thomas Adams, Chairman of the Board Appointed Interim CEO SAN DIEGO, CA June 22, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted t
Read more →CRDFTrovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga in Patients with mCRPC Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and M
Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga in Patients with mCRPC Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and rec
Read more →CRDFTrovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the second dosi
Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in do
Read more →CRDFTrovagene, Inc. Announces Closing of $18 Million Public Offering
Trovagene, Inc. Announces Closing of $18 Million Public Offering SAN DIEGO, June 12, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced t
Read more →CRDFTrovagene, Inc. Announces Reverse Stock Split SAN DIEGO, May 31 , 2018 Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and
Trovagene, Inc. Announces Reverse Stock Split SAN DIEGO, May 31 , 2018 Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, announced today, a reverse split of i
Read more →CRDFTrovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-07
Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with low-dose cytarabine (LDAC) in dose-escalation phase o
Read more →CRDFTrovagene Announces First Quarter 2018 Highlights and Financial Results
Trovagene Announces First Quarter 2018 Highlights and Financial Results SAN DIEGO, CA May 8, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies to treat hematologic and solid tumor cancers, today announced company
Read more →CRDFTrovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine Methodology to assess changes in leukemic cells, genomic alterations and pTCTP st
Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b/2 Clinical Trial of PCM-075. Update on c
Read more →CRDFTrovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor,
Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition a
Read more →CRDFTrovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 SAN DIEGO, CA April 12th, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company,
Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting SAN DIEGO, CA April 12th, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematolog
Read more →CRDFTrovagene to Present at the 26 th Annual Wall Street Investor Conference
Trovagene to Present at the 26th Annual Wall Street Investor Conference SAN DIEGO, CA March 20, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor cancers, announce
Read more →CRDFTrovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial SAN DIEGO, CA March 5, 2018 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted ca
Read more →CRDFTrovagene Announces Fourth Quarter and Full-Year 2017 Results
Trovagene Announces Fourth Quarter and Full-Year 2017 Results SAN DIEGO, CA February 26, 2018 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor cancers, today announce
Read more →CRDFTrovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML Yale Cancer Center and Kansas University Cancer Center now actively screening and enro
Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Mye
Read more →CRDFTrovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium Targeted treatment with highly-selective Polo-like Kinas
Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium Targeted treatment with highly-selective Polo-like Kinase 1 inhibitor PCM-075 in combination with Zytiga (abiratero
Read more →CRDFTrovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)
Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML) SAN DIEGO, CA February 6, 2018 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced t
Read more →CRDFTrovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) PCM-075, Trovagene s highly-selective Polo-like Kinase 1 (PLK1) inhibitor
Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) PCM-075, Trovagene s highly-selective Polo-like Kinase 1 (PLK1) inhibitor may extend patient response to therapy when used in combin
Read more →CRDFTrovagene to Present at the Biotech Showcase Annual Conference
Trovagene to Present at the Biotech Showcase Annual Conference SAN DIEGO, CA January 3, 2018 Trovagene, Inc. (NASDAQ: TROV), an oncology precision medicine biotechnology company, today announced that it will present at Biotech Showcase 2018 to be held January 8-10, at the Hilto
Read more →CRDFTrovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with stan
Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and prelimin
Read more →CRDFTrovagene Prices $4.5 Million Public Offering
Trovagene Prices $4.5 Million Public Offering SAN DIEGO, CA December 15, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the pricing of a public offering of 15,000,000 shares of its common stock (or common stock equivalents) and
Read more →CRDFTrovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for Metastatic Castration-Resistant Prostate Cancer PCM-075, Trovagene s Polo-like Kinase 1 (PLK1) inhibitor enhances act
Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for Metastatic Castration-Resistant Prostate Cancer PCM-075, Trovagene s Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represen
Read more →CRDFTrovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers
Trovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers SAN DIEGO, CA December 12, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its pr
Read more →CRDFTrovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga at San Antonio Breast Cancer Symposium (SABCS) Targeted treatment with highly selective Po
Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga at San Antonio Breast Cancer Symposium (SABCS) Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new op
Read more →CRDFTransforming Oncology With Precision Cancer Therapeutics Company Overview november, 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the mea
Transforming Oncology With Precision Cancer Therapeutics Company Overview november, 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 199
Read more →CRDFTrovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standa
Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminar
Read more →CRDFTrovagene Announces Third Quarter 2017 Company Highlights and Financial Results
Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results SAN DIEGO, CA November 9, 2017 Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third quarte
Read more →CRDFTrovagene s PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may repre
Trovagene s PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti
Read more →CRDFFDA Grants Orphan Drug Designation to Trovagene s PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
FDA Grants Orphan Drug Designation to Trovagene s PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) SAN DIEGO, CA October 9, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision-medicine, biotechnology company, today announced that the U.S. Food and Drug Adm
Read more →CRDFTransforming Oncology With Precision Cancer Therapeutics Company Overview september, 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the me
Transforming Oncology With Precision Cancer Therapeutics Company Overview september, 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 19
Read more →CRDFTrovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis Dr. Athena Countouriotis joins Trovagene s Board of Directors, bringing significant experience in oncolog
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis Dr. Athena Countouriotis joins Trovagene s Board of Directors, bringing significant experience in oncology clinical development and orphan indications SAN DIEGO, C
Read more →CRDFTrovagene Announces Participation at the 19 th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 SAN DIEGO, CA August 31, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it will be featured
Read more →CRDFTrovagene s PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted ther
Trovagene s PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologi
Read more →CRDFTrovagene s PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizart
Trovagene s PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor reg
Read more →CRDFTrovagene Announces Second Quarter 2017 Company Highlights and Financial Results
Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results SAN DIEGO, CA August 9, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the second quarter ended June 30
Read more →CRDFTrovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute
Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute SAN DIEGO, CA July 28, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that Trovagene, and Antonius Schuh and Stephen Zaniboni, the company s former Chief E
Read more →CRDFTrovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of th
Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor
Read more →CRDFTrovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor Greater selectivity for PLK1, potency, oral bioavailability and short half-life
Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075 s potential as safe and effective treatm
Read more →CRDFTrovagene Announces $7.1 Million Registered Direct Offering
Trovagene Announces $7.1 Million Registered Direct Offering SAN DIEGO, July 14, 2017 /PRNewswire/ Trovagene, Inc. (NASDAQ:TROV), a precision medicine biotechnology company, today announced it has entered into a securities purchase agreement with certain accredited investors to
Read more →CRDFTrovagene Announces Agreement with Novogene for NextCollect in China
Trovagene Announces Agreement with Novogene for NextCollect in China SAN DIEGO, CA July 12, 2017 Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutt
Read more →CRDFTrovagene, Inc. Regains Compliance with NASDAQ Listing Requirements
Trovagene, Inc. Regains Compliance with NASDAQ Listing Requirements SAN DIEGO, CA July 10, 2017 Trovagene, Inc. (NASDAQ:TROV), a precision medicine biotechnology company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) indicating that the Compan
Read more →CRDFTrovagene Engages CRO to Conduct Phase 1b/2 Trial of PCM-075 in
Trovagene Engages CRO to Conduct Phase 1b/2 Trial of PCM-075 in AML SAN DIEGO, CA July 6, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that is has formally engaged PRA Health Sciences (NASDAQ: PRAH), a leading contract research
Read more →CRDFTrovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial
Trovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial SAN DIEGO, CA June 29, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it has executed a supplier agreement with NerPharMa, S.r.l., a p
Read more →CRDFTrovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia
Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia SAN DIEGO, CA June 27, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the submissi
Read more →CRDFTrovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia
Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia SAN DIEGO, CA June 26, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Patent and Trademark Office, and separately,
Read more →CRDFTrovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials
Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials SAN DIEGO, CA June 22, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company today announced it has entered into an
Read more →CRDFTrovagene Enters Into Agreement with AstraZeneca to Utilize Trovera ctDNA Test and Services in Prospective Biomarker Study
Trovagene Enters Into Agreement with AstraZeneca to Utilize Trovera ctDNA Test and Services in Prospective Biomarker Study SAN DIEGO, June 12, 2017 /PRNewswire/ Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company today announced it has entered into an agre
Read more →CRDFPhase 1 Safety Study Supports Planned Development of PCM-075 in AML Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or meta
Phase 1 Safety Study Supports Planned Development of PCM-075 in AML Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors SAN DIEGO, CA May 25, 2017 Trovagene,
Read more →CRDFTrovagene to Present at the 7th Annual LD Micro Invitational Conference on
Trovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angeles SAN DIEGO, CA May 23, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be pre
Read more →CRDFTrovagene Announces First Quarter 2017 Company Highlights and Financial Results
Trovagene Announces First Quarter 2017 Company Highlights and Financial Results SAN DIEGO, CA May 10, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2
Read more →CRDFTransforming Oncology With Precision Cancer Therapeutics Company Overview may 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning o
Transforming Oncology With Precision Cancer Therapeutics Company Overview may 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The
Read more →CRDFTrovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday
Trovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017 SAN DIEGO, CA April 26, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that it will report financial results for the f
Read more →CRDFTrovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on
Trovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City SAN DIEGO, CA April 25, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be prese
Read more →CRDFTrovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board
Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board SAN DIEGO, CA April 13, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that Dr. Sandra Silberman, a leading clinical researcher in hematology
Read more →CRDFTransforming Oncology With Precision Cancer Therapeutics Company Overview march 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning
Transforming Oncology With Precision Cancer Therapeutics Company Overview march 2017 Company Overview January 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. T
Read more →CRDFTrovagene to Present at The MicroCap Conference on
Trovagene to Present at The MicroCap Conference on April 4, 2017 in New York City SAN DIEGO, CA March 27, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at this yea
Read more →CRDFTrovagene to Present at the Sidoti & Company Spring 2017 Convention
Trovagene to Present at the Sidoti & Company Spring 2017 Convention SAN DIEGO, CA March 21, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will present at the Sidoti & Company Spring
Read more →CRDFTrovagene Reports Fourth Quarter and Year End 2016 Financial Results Announces restructuring program to support its expansion into precision cancer therapeutics
Trovagene Reports Fourth Quarter and Year End 2016 Financial Results Announces restructuring program to support its expansion into precision cancer therapeutics SAN DIEGO, CA March 15, 2017 Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company today reporte
Read more →CRDFTrovera TM EGFR Urine Liquid Biopsy Test Predictive of Clinical Response to Therapy: Case Series in Patients with Non-Small Cell Lung Cancer Authors conclude that ctDNA testing demonstrates clinical utility in assessing
TroveraTM EGFR Urine Liquid Biopsy Test Predictive of Clinical Response to Therapy: Case Series in Patients with Non-Small Cell Lung Cancer Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy SAN DIEGO, CA March
Read more →CRDFTrovagene to Announce Fourth Quarter and Year End 2016 Financial Results and Accomplishments and Host Conference Call on Wednesday
Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and Accomplishments and Host Conference Call on Wednesday, March 15, 2017 SAN DIEGO, CA March 1, 2017 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, anno
Read more →CRDFTrovagene to Attend the 29th Annual ROTH Conference
Trovagene to Attend the 29th Annual ROTH Conference SAN DIEGO, CA February 28, 2017 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton
Read more →CRDFPublication of Trovera KRAS liquid biopsy test demonstrates clinical utility in advanced cancers for detection and measurement of therapeutic response Performance of Trovera ctDNA KRAS in blood and urine has similar conc
Publication of Trovera KRAS liquid biopsy test demonstrates clinical utility in advanced cancers for detection and measurement of therapeutic response Performance of Trovera ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics S
Read more →CRDFTrovagene Announces Broadening Network of Commercial Distributors Seven new partners to commercialize Trovera TM liquid biopsy tests in Europe and the Middle East
Trovagene Announces Broadening Network of Commercial Distributors Seven new partners to commercialize TroveraTM liquid biopsy tests in Europe and the Middle East SAN DIEGO, CA January 12, 2017 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) technolo
Read more →CRDFTransforming Oncology With Precision Medicine Solutions Company Overview January 2017 Forward-looking statements Statements in this presentation about the Company's expectations, applications of its technology, markets,
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 Forward-looking statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historica
Read more →CRDFTrovagene announces a reorganization to accelerate global distribution of liquid biopsy technology
Trovagene announces a reorganization to accelerate global distribution of liquid biopsy technology SAN DIEGO, CA December 13, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it will increase its focus
Read more →CRDFTrovagene and Boreal Genomics Announce Strategic Partnership Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution
Trovagene and Boreal Genomics Announce Strategic Partnership Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution SAN DIEGO, CA November 30, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumo
Read more →CRDFWorld Lung Conference Features Data Demonstrating Clinical Utility and Cost Effectiveness of Trovagene s Liquid Biopsy Tests for Mutation Detection and Monitoring in NSCLC Patients
World Lung Conference Features Data Demonstrating Clinical Utility and Cost Effectiveness of Trovagene s Liquid Biopsy Tests for Mutation Detection and Monitoring in NSCLC Patients SAN DIEGO, CA November 28, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor D
Read more →CRDFTrovagene to Attend the 28th Annual Piper Jaffray Healthcare Conference
Trovagene to Attend the 28th Annual Piper Jaffray Healthcare Conference SAN DIEGO, CA November 22, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 28th Annual Piper Jaffray Healthcare Conference,
Read more →CRDFTrovagene Reports Third Quarter 2016 Financial Results and Accomplishments
Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments SAN DIEGO, CA November 9, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the third qu
Read more →CRDFTrovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office, Broadening Its Precision Cancer Monitoring IP Portfolio
Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office, Broadening Its Precision Cancer Monitoring IP Portfolio SAN DIEGO, CA November 7, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today
Read more →CRDFTrovagene Schedules Release of Third Quarter 2016 Financial Results and Investor Conference Call
Trovagene Schedules Release of Third Quarter 2016 Financial Results and Investor Conference Call SAN DIEGO, CA November 2, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it will report financial resul
Read more →CRDFTrovagene s Liquid Biopsy in Ground Breaking National Initiative to Transform Outcomes for Pancreatic Cancer Patients Trovera TM liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leadin
Trovagene s Liquid Biopsy in Ground Breaking National Initiative to Transform Outcomes for Pancreatic Cancer Patients TroveraTM liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively asse
Read more →CRDFoverview Forward-looking statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts constitute
Forward-looking statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts constitute forward-looking statements for purposes of the safe harbor provision
Read more →CRDFTrovagene to Present at the 3rd Annual Precision Medicine Congress
Trovagene to Present at the 3rd Annual Precision Medicine Congress SAN DIEGO, CA September 9, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced that its Chief Scientific Officer, Mark Erlander, PhD, will pres
Read more →CRDFBlue Cross Blue Shield Illinois to Cover Trovera Liquid Biopsy Tests BCBS Illinois expands patient access to Trovera TM tests for 8.1million covered lives
Blue Cross Blue Shield Illinois to Cover Trovera Liquid Biopsy Tests BCBS Illinois expands patient access to TroveraTM tests for 8.1million covered lives SAN DIEGO, CA August 17, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnos
Read more →CRDFTrovera Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis shoul
Trovera Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis should be considered in treatment decision-making SAN DIEGO, CA
Read more →CRDFTrovagene Reports Second Quarter 2016 Financial Results and Accomplishments
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments SAN DIEGO, CA August 4, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the second qu
Read more →CRDFDiagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) dia
Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) diagnosis in urine and blood with high sensitivity and specifi
Read more →CRDFTrovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera ctDNA Liquid Biopsy Tests in Patient Care
Trovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera ctDNA Liquid Biopsy Tests in Patient Care SAN DIEGO, CA July 12, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today anno
Read more →CRDFTrovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer Trovagene s KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Di
Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer Trovagene s KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Diane Simeone at University of Michigan Health System SAN DI
Read more →CRDFASCO Oral Presentation Demonstrates Trovagene s Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer Results validate urine ctDNA testing as an alternative to tissue and plasm
ASCO Oral Presentation Demonstrates Trovagene s Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer Results validate urine ctDNA testing as an alternative to tissue and plasma based on a large prospective study of T790M detection and
Read more →CRDFLarge Clinical Data Set in Lung Cancer Featuring Trovagene s Precision Cancer Monitoring Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting Results from 213 patient study demonstrates use of urinary
Large Clinical Data Set in Lung Cancer Featuring Trovagene s Precision Cancer Monitoring Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detect
Read more →CRDFLarge Clinical Study Demonstrates High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients; Results Presented at 2016 AACR Pancreatic Cancer Meeting 92.9% of metastatic pancreatic cancer pa
Large Clinical Study Demonstrates High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients; Results Presented at 2016 AACR Pancreatic Cancer Meeting 92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene s Pre
Read more →CRDFTrovagene Announces First Quarter 2016 Financial Results
Trovagene Announces First Quarter 2016 Financial Results SAN DIEGO, CA May 10, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016. I m thrilled to join Trovagene to
Read more →CRDFTrovagene Appoints Bill Welch as Chief Executive Officer
Trovagene Appoints Bill Welch as Chief Executive Officer SAN DIEGO, CA April 25, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the appointment of William (Bill) Welch as Chief Executive Officer, effective immediately. In add
Read more →CRDFPatient Case Report Demonstrating the Ability of Trovagene s Precision Cancer Monitoring Platform to Determine Early Drug Response Published in Cancer Discovery Confirmation of BRAF V600E mutational status and quantitati
Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to Determine Early Drug Response Published in Cancer Discovery Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary ctDNA used to assess re
Read more →CRDFTrovagene Enters Into Preferred Provider Agreement with Stratose PPO Network
Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network SAN DIEGO, April 11, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an Agreement with Stratose, Inc., estab
Read more →CRDFClinical Data Featuring Trovagene s Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference Urinary liquid biopsy shown to monitor early drug response to anti-EGFR therapy
Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference Urinary liquid biopsy shown to monitor early drug response to anti-EGFR therapy SAN DIEGO, April 7, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV)
Read more →CRDFTrovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause
Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause SAN DIEGO, CA March 28, 2016 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that its Board of Directors terminated the employment of CEO
Read more →CRDFClinical Study Results Featuring Trovagene s Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 High clinical sensitivity and longitudinal monitoring of KRAS mutations across multiple ca
Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 High clinical sensitivity and longitudinal monitoring of KRAS mutations across multiple cancer types demonstrated in urine SAN DIEGO, March 24, 2016
Read more →CRDFC O R R E C T I O N -- Trovagene, Inc./ In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company t
/C O R R E C T I O N -- Trovagene, Inc./ In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that in the Condensed Consolidated Statements of Operations
Read more →CRDFTrovagene Announces Fourth Quarter and Year End 2015 Financial Results
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results SAN DIEGO, March 10, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31,
Read more →CRDFTrovagene Enters Into Preferred Provider Agreement with Multiplan, Inc. Agreement expands in-network health benefit access to Trovagene s Precision Cancer Monitoring platform for an additional 68 million covered lives
Trovagene Enters Into Preferred Provider Agreement with Multiplan, Inc. Agreement expands in-network health benefit access to Trovagene's Precision Cancer Monitoring platform for an additional 68 million covered lives SAN DIEGO, March 1, 2016 /PRNewswire/ -- Trovagene, Inc. (NA
Read more →CRDFTrovagene Schedules Release of Fourth Quarter and Year End 2015 Financial Results and Investor Conference Call
Trovagene Schedules Release of Fourth Quarter and Year End 2015 Financial Results and Investor Conference Call SAN DIEGO, Feb. 29, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial r
Read more →CRDFTrovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network
Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network SAN DIEGO, Feb. 24, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an Agreement with Three Rivers
Read more →CRDFTrovagene Enters into Preferred Provider Agreement with Fortified Provider Network
Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network SAN DIEGO, Feb. 22, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an Agreement with Fortified Provid
Read more →CRDFTrovagene to Present at Leerink Partners 5th Annual Global Healthcare Conference
Trovagene to Present at Leerink Partners 5th Annual Global Healthcare Conference SAN DIEGO, Feb. 8, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Chief Executive Officer, Antonius Schuh, Ph.D., is sc
Read more →CRDFTrovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform FedMed brings in-network health plan access to an additional 40 million covered lives
Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform FedMed brings in-network health plan access to an additional 40 million covered lives DIEGO, Feb. 1, 2016 /PRNewswire/ -- Trovagene, Inc. (NASD
Read more →CRDFTrovagene Announces Agreement with America s Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform Agreement provides in-network coverage for 22 million individuals
Trovagene Announces Agreement with America s Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform Agreement provides in-network coverage for 22 million individuals SAN DIEGO, CA January 21, 2016 Trovagene, Inc. (NASDAQ: TROV), a dev
Read more →CRDFJanuary 2016 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other sta
January 2016 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are forward-looking s
Read more →CRDFtrovagene DNA November 2015 Better Cancer Monitoring with Cell-Free Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests an
'trovagene DNA November 2015 Better Cancer Monitoring with Cell-Free Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are forwa
Read more →CRDFTrovagene Announces Patent Issuance, Broadening its Precision Cancer Monitoring IP Portfolio
Trovagene Announces Patent Issuance, Broadening its Precision Cancer Monitoring IP Portfolio SAN DIEGO, CA December 16, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that the U.S. Patent and Trademark Office has issued Paten
Read more →CRDFTrovagene to Present at 27 th Annual Piper Jaffray Healthcare Conference and Attend Evercore ISI Investor Conference
Trovagene to Present at 27th Annual Piper Jaffray Healthcare Conference and Attend Evercore ISI Investor Conference SAN DIEGO, CA November 25, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antoni
Read more →CRDFNovember 2015 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other st
November 2015 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are forward-looking
Read more →CRDFTrovagene, Inc. Announces Third Quarter 2015 Financial Results
Trovagene, Inc. Announces Third Quarter 2015 Financial Results SAN DIEGO, CA November 9, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2015. Duri
Read more →CRDFClinical Data Featuring Trovagene s Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Interim results from a colorectal cance
Clinical Data Featuring Trovagene s Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Interim results from a colorectal cancer study adds to the body of clinical evidence supporting Tr
Read more →CRDFTrovagene s Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study Data for the detection and monitoring of EGFR T790M mutations to be presented at the AACR-NCI-EORTC Internation
Trovagene s Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study Data for the detection and monitoring of EGFR T790M mutations to be presented at the AACR-NCI-EORTC International Conference Analysis demonstrates correlation of clinica
Read more →CRDFClinical Data for Trovagene s Precision Cancer Monitoring Platform Presented at the European Cancer Congress Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapi
Clinical Data for Trovagene s Precision Cancer Monitoring Platform Presented at the European Cancer Congress Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapidly detect treatment response SAN DIEGO, CA September 24,
Read more →CRDFResults from Second Large-Scale Clinical Trial for Trovagene s Urine-based HPV Test Released Data presented at the 30th International Papillomavirus Conference; general population screening trial is ongoing
Results from Second Large-Scale Clinical Trial for Trovagene s Urine-based HPV Test Released Data presented at the 30th International Papillomavirus Conference; general population screening trial is ongoing SAN DIEGO, CA September 21, 2015 Trovagene, Inc. (NASDAQ: TROV), a deve
Read more →CRDFTrovagene Forms European Institute with Alberto Bardelli, Ph.D.; Core Technologies Transferred from University of Torino Trovagene Research Institute aims to improve cancer care through advanced genomic solutions with th
Trovagene Forms European Institute with Alberto Bardelli, Ph.D.; Core Technologies Transferred from University of Torino Trovagene Research Institute aims to improve cancer care through advanced genomic solutions with the mission of accelerating adoption of Trovagene s Precision
Read more →CRDFTrovagene s Urine-Based Liquid Biopsy Platform Shown to Detect Impact of Cancer Therapy within 24 Hours Clinical Data to be Presented in Oral Session on Liquid Biopsies at the 16th World Conference on Lung Cancer
Trovagene s Urine-Based Liquid Biopsy Platform Shown to Detect Impact of Cancer Therapy within 24 Hours Clinical Data to be Presented in Oral Session on Liquid Biopsies at the 16th World Conference on Lung Cancer SAN DIEGO, CA September 9, 2015 Trovagene, Inc. (NASDAQ: TROV), a
Read more →CRDFTrovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7 th Annual Next Generation Dx Summit Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility
Trovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7th Annual Next Generation Dx Summit Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility of Trovagene s Precision Cancer Monitoring platform as an im
Read more →CRDFTrovagene, Inc. Announces Second Quarter 2015 Financial Results
Trovagene, Inc. Announces Second Quarter 2015 Financial Results SAN DIEGO, CA August 10, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2015. Our pilot
Read more →CRDFTrovagene, Inc. Announces Closing of Public Offering of Common Stock San Diego, CA
Trovagene, Inc. Announces Closing of Public Offering of Common Stock San Diego, CA, July 22, 2015 Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering. The Company sold 4,600,000 shares of its common stock in the off
Read more →CRDFTrovagene, Inc. Announces Pricing of Public Offering of Common Stock
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock SAN DIEGO, CA, July 17, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stoc
Read more →CRDFTrovagene, Inc. Announces Public Offering of Common Stock
Trovagene, Inc. Announces Public Offering of Common Stock SAN DIEGO, CA, July 16, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The o
Read more →CRDFTrovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform Study objective is to deliver a urinary liquid biopsy-based solution to provide faster an
Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform Study objective is to deliver a urinary liquid biopsy-based solution to provide faster and more accurate information for measuring response to immun
Read more →CRDFTrovagene Inc. to Present at Cantor Fitzgerald s Inaugural Healthcare Conference
Trovagene Inc. to Present at Cantor Fitzgerald s Inaugural Healthcare Conference SAN DIEGO, CA July 7, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present
Read more →CRDFJuly, 2015 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other state
Confidential 42 Continue to demonstrate clinical utility Expand mutation coverage on PCM platform Initiate new collaborations to establish clinical utility Establish strategic partnerships to grow market reach Drive adoption and clinical value of PCM platform 20+ abstracts in 201
Read more →CRDFTrovagene Upgraded to Russell 3000, Small Cap and Global Indexes
Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes SAN DIEGO, CA June 29, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that the Company is now included in the Russell 3000 , the Russell 2000 Small Cap, and Rus
Read more →CRDFClinical Data Featuring Trovagene s Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences Data support the clinical utility of using the Company s Precision Cancer Monitoring technology i
Clinical Data Featuring Trovagene s Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences Data support the clinical utility of using the Company s Precision Cancer Monitoring technology in the management of non-small cell lung and colorectal canc
Read more →CRDFTrovagene Launches Commercial Marketing Campaign at the 2015 American Society of Clinical Oncology Annual Meeting Expanded physician access program, new awareness campaign, and clinical data presentations at ASCO highlig
Trovagene Launches Commercial Marketing Campaign at the 2015 American Society of Clinical Oncology Annual Meeting Expanded physician access program, new awareness campaign, and clinical data presentations at ASCO highlight the Company s urine-based liquid biopsy service SAN DIE
Read more →CRDFMay, 2015 Better Cancer Monitoring with Cell-Free DNA Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statem
Confidential 46 Demonstrate clinical utility Expand mutation coverage on PCM platform Initiate new collaborations to establish clinical utility Establish strategic partnerships to grow market reach Drive early adoption in top cancer centers and integrated healthcare networks 20+
Read more →CRDFClinical Utility of Trovagene s Urine-Based Liquid Biopsy Platform to Be Highlighted at the American Society of Clinical Oncology Meeting Precision Cancer Monitoring SM technology offers advantages over tissue biopsy and
Clinical Utility of Trovagene s Urine-Based Liquid Biopsy Platform to Be Highlighted at the American Society of Clinical Oncology Meeting Precision Cancer MonitoringSM technology offers advantages over tissue biopsy and demonstrates ability to monitor tumor dynamics in lung, pan
Read more →CRDFTrovagene, Inc. Announces First Quarter 2015 Financial Results Company moves three EGFR mutation assays into its CLIA lab, expands clinical study programs in lung cancer, and prepares to deploy commercial strategy and sa
Trovagene, Inc. Announces First Quarter 2015 Financial Results Company moves three EGFR mutation assays into its CLIA lab, expands clinical study programs in lung cancer, and prepares to deploy commercial strategy and sales team ahead of ASCO SAN DIEGO, CA May 5, 2015 - Trovage
Read more →CRDFCost Benefit Analysis of Trovagene s Precision Cancer Monitoring Solution to Be Presented at the Association for Value-Based Cancer Care in Washington, DC Analysis concludes that use of Trovagene s urinary liquid biopsy
Cost Benefit Analysis of Trovagene s Precision Cancer Monitoring Solution to Be Presented at the Association for Value-Based Cancer Care in Washington, DC Analysis concludes that use of Trovagene s urinary liquid biopsy significantly reduces costs when compared to tissue biopsy
Read more →CRDFTrovagene Schedules Release of First Quarter 2015 Financial Results and Investor Conference Call SAN DIEGO, CA April 28 , 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced tod
Trovagene Schedules Release of First Quarter 2015 Financial Results and Investor Conference Call SAN DIEGO, CA April 28 , 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the three mont
Read more →CRDFTrovagene s Urine-Based HPV Assay to Be Featured in Presentation at the 13 th Annual Cervical Cancer Conference and HPV Consortium in Beijing Presentation to include results from PREDICTORS 4 study showing high sensitivi
Trovagene s Urine-Based HPV Assay to Be Featured in Presentation at the 13th Annual Cervical Cancer Conference and HPV Consortium in Beijing Presentation to include results from PREDICTORS 4 study showing high sensitivity and potential for non-invasive test to be made available
Read more →CRDFPoster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of Trovagene s ctDNA Precision Cancer Monitoring Platform Company s liquid biopsy technology features single molecule sensit
Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of Trovagene s ctDNA Precision Cancer Monitoring Platform Company s liquid biopsy technology features single molecule sensitivity and the ability to obtain significantly more circulat
Read more →CRDFTrovagene s Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients Non-invasive liquid biopsy enables detection of emerging T790M muta
Trovagene s Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and month
Read more →CRDFMatthew Posard Joins Trovagene s Executive Management Team as Chief Commercial Officer Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging inno
Matthew Posard Joins Trovagene s Executive Management Team as Chief Commercial Officer Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging innovative applications of next-generation sequencing San Dieg
Read more →CRDFTrovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care
Trovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care SAN DIEGO, CA March 12, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecu
Read more →CRDFTrovagene, Inc. to Present at Leerink Global Healthcare Conference
Trovagene, Inc. to Present at Leerink Global Healthcare Conference SAN DIEGO, Feb. 10, 2015 /PRNewswire/ Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate
Read more →CRDFClinical Results Demonstrate High Sensitivity of Trovagene s Urine-Based HPV Assay for the Detection of High Risk HPV and Pre-Cancerous Cervical Lesions Large-scale study shows potential for non-invasive test to be made
Clinical Results Demonstrate High Sensitivity of Trovagene s Urine-Based HPV Assay for the Detection of High Risk HPV and Pre-Cancerous Cervical Lesions Large-scale study shows potential for non-invasive test to be made available to millions of women worldwide who are unscreened
Read more →CRDFBetter Cancer Monitoring with Cell-Free DNA February, 2015 Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other s
Key Components for Full Commercialization in 2015 Copyright 2015 Trovagene, Inc. | Confidential 34 Full Commercialization (2015) Drive Adoption of Expanded Menu Conversion of Research Collaborators to Clinical Adopters Expand New Market Segments New Market for Genomic Monitoring
Read more →CRDFTrovagene s Chief Scientific Officer to Present Precision Cancer Monitoring SM Platform Overview at the Personalized Medicine World Conference Mountain View, Calif.
Trovagene s Chief Scientific Officer to Present Precision Cancer MonitoringSM Platform Overview at the Personalized Medicine World Conference Mountain View, Calif. Jan. 26, 2015 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that
Read more →CRDFTrovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring Prospective clinical studies to evaluate Trovagene s Precision Cancer Monitoring platform to
Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring Prospective clinical studies to evaluate Trovagene s Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circ
Read more →CRDFClinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene s Precision Cancer Monitorin g SM Platform in Colorectal and Pancreatic Cancer Patients Trovagene s proprietary
Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene s Precision Cancer MonitoringSM Platform in Colorectal and Pancreatic Cancer Patients Trovagene s proprietary KRAS assay enables physicians to determine mutational status,
Read more →CRDFTrovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients Company expands lung cancer clinical program for its Precis
Trovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients Company expands lung cancer clinical program for its Precision Cancer MonitoringSM solution to up to 700 patients at t
Read more →CRDFTrovagene and City of Hope Collaborate To Monitor EGFR Mutational Status in Lung Cancer Patients Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad r
Trovagene and City of Hope Collaborate To Monitor EGFR Mutational Status in Lung Cancer Patients Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad range of clinically actionable mutations in major cancer typ
Read more →CRDFTrovagene to Present at the 7 th Annual Biotech Showcase Conference
Trovagene to Present at the 7th Annual Biotech Showcase Conference SAN DIEGO January 7, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will provide an update on the Company s
Read more →CRDFFormer President of BIO Joins Trovagene s Board of Directors
Former President of BIO Joins Trovagene s Board of Directors SAN DIEGO January 6, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Carl Feldbaum, president emeritus of the Biotechnology Industry Organization (BIO), the wor
Read more →CRDFTrovagene Announces Presentation of Clinical Data at the 56 th Annual American Society of Hematology Meeting
Trovagene Announces Presentation of Clinical Data at the 56th Annual American Society of Hematology Meeting SAN FRANCISCO December 4, 2014 Trovagene, Inc. (NASDAQ: TROV), today announced that clinical data will be presented at the 56th Annual American Society of Hematology (ASH)
Read more →CRDFTrovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients Data presented at the EORTC-NCI-AACR International Symposium Demonstrate
Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with
Read more →CRDFTrovagene, Inc. Announces Third Quarter 2014 Financial Results
Trovagene, Inc. Announces Third Quarter 2014 Financial Results SAN DIEGO, CA November 6, 2014 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2014. The
Read more →CRDFBetter Cancer Monitoring with Cell-Free DNA October 2014 Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other sta
Key Components for Full Commercialization in 2015 Copyright 2014 Trovagene, Inc. 31 Full Commercialization (2015) Drive Adoption of Expanded Menu Conversion of Research Collaborators to Clinical Adopters Expand New Market Segments New Market for Genomic Monitoring Direct sales te
Read more →CRDFTrovagene Provides Update on Its Urine-Based HPV Test
Trovagene Provides Update on Its Urine-Based HPV Test SAN DIEGO, Aug. 20, 2014 /PRNewswire/ Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillom
Read more →CRDFTrovagene, Inc. Announces Second Quarter 2014 Financial Results
Trovagene, Inc. Announces Second Quarter 2014 Financial Results SAN DIEGO, CA August 7, 2014 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014. Trovagene i
Read more →CRDFTrovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation por
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation portfolio for cancer monitoring SAN DIEGO July 1, 2014 Trovag
Read more →CRDFStephen Zaniboni | Chief Financial Officer Jefferies 2014 Global Healthcare Conference
Completed assays will be transferred to Trovagene s CLIA laboratory in 2014 2014 Development Program For Cancer Monitoring Applications ASSAY DEVELOPMENT PROGRAM EGFR L858R BRAF Quant HER-2 Corporate Development Strategies Collaborations with large strategic diagnostic and life s
Read more →CRDFTrovagene s Precision Cancer Monitoring Technology Referenced in Multi-Disciplinary Clinical Consensus Guidelines Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as
Trovagene s Precision Cancer Monitoring Technology Referenced in Multi-Disciplinary Clinical Consensus Guidelines Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility SAN DIEGO, CA May 28,
Read more →CRDFTrovagene Announces Publication of Data from Clinical Validation Program Using Its Precision Cancer Monitoring Platform Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene m
Trovagene Announces Publication of Data from Clinical Validation Program Using Its Precision Cancer Monitoring Platform Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO, CA May 2
Read more →CRDFTrovagene, Inc. Announces First Quarter 2014 Financial Results
Trovagene, Inc. Announces First Quarter 2014 Financial Results SAN DIEGO, CA May 12, 2014 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2014. Our focus is to demonstrate
Read more →CRDFAntonius Schuh, Ph.D. | Chief Executive Officer April 2014 Better Cancer Monitoring with Cell-Free DNA in Urine Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of
Corporate Development Strategies Collaborations with large strategic companies Accelerate our core strategic mission in cancer monitoring Create out-licensing opportunities with potential for incremental revenue streams 2014/14 R&D collaborations include PerkinElmer (NYSE PKI) an
Read more →CRDFClinical Data Presented at AACR Demonstrate Ability of Trovagene s Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients Response to Therapy Study results show correlation between mutational status and tr
Clinical Data Presented at AACR Demonstrate Ability of Trovagene s Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients Response to Therapy Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V60
Read more →CRDFTrovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results Expanding Cancer Monitoring Platform with Additional Oncogene Mutation Assays, Building Clinical Evidence to Facilitate Broad Adoption
Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results Expanding Cancer Monitoring Platform with Additional Oncogene Mutation Assays, Building Clinical Evidence to Facilitate Broad Adoption SAN DIEGO, CA March 17, 2014 Trovagene, Inc. (NASDAQ: TROV), a deve
Read more →CRDFDr. Rodney S. Markin Joins Trovagene s Board of Directors
Dr. Rodney S. Markin Joins Trovagene s Board of Directors SAN DIEGO, CA February 19, 2014 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company s Board of Directors. Dr. Markin is a hepati
Read more →CRDFAntonius Schuh, Ph.D. | Chief Executive Officer February 2014 Better Cancer Monitoring with Cell-Free DNA in Urine Forward-Looking Statements Statements in this presentation about the Company's expectations, applications
Corporate Development Strategies Collaborations with large strategic companies Accelerate our core strategic mission in cancer monitoring Create out-licensing opportunities with potential for incremental revenue streams 2014/14 R&D collaborations include PerkinElmer (NYSE PKI) an
Read more →CRDFBetter Cancer Monitoring with Cell-Free DNA in Urine Antonius Schuh, Ph.D. | Chief Executive Officer January 2014 Forward-Looking Statements Statements in this presentation about the Company's expectations, applications
Corporate Development Strategies Collaborations with large strategic companies Accelerate our core strategic mission in cancer monitoring Create out-licensing opportunities with potential for incremental revenue streams 2014/14 R&D collaborations include PerkinElmer (NYSE PKI) an
Read more →CRDFTrovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer SAN DIEGO, CALIF. and
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer SAN DIEGO, CALIF. and THE WOODLANDS, TEXAS January 6, 2014 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnost
Read more →CRDFTrovagene, Inc. Reports Third Quarter 2013 Financial Results First clinical results presented on novel molecular diagnostics to optimize cancer treatment; Ends quarter with approximately $28 million in cash
Trovagene, Inc. Reports Third Quarter 2013 Financial Results First clinical results presented on novel molecular diagnostics to optimize cancer treatment; Ends quarter with approximately $28 million in cash SAN DIEGO, CA November 14, 2013 Trovagene, Inc. (NASDAQ: TROV), a devel
Read more →CRDFDr. Paul Billings Joins Trovagene s Board of Directors
Dr. Paul Billings Joins Trovagene s Board of Directors SAN DIEGO, CA October 30, 2013 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Paul R. Billings has been appointed to the Company s Board of Directors. A board certifi
Read more →CRDFA better clinical pathway for cancer monitoring Antonius Schuh, Ph.D. | Chief Executive Officer October 2013 Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of it
Patent for NPM mutants to diagnose and monitor acute myeloid leukemia Issued European patent for detection of pathogenic infections Improved liquidity and access to capital Completed public offering of $10 million and began trading on NASDAQ Added to the Russell microcap and the
Read more →CRDFFirst Prospective Cancer Monitoring Data Released Indicating that Oncogene Mutation Signal in Urine Correlates with Response to Therapy Initial data from ongoing clinical study presented by MD Anderson Cancer Center and
First Prospective Cancer Monitoring Data Released Indicating that Oncogene Mutation Signal in Urine Correlates with Response to Therapy Initial data from ongoing clinical study presented by MD Anderson Cancer Center and Trovagene at AACR-NCI-EORTC International Conferences highl
Read more →CRDFTrovagene collaborates with USC in a clinical study evaluating cancer monitoring technology Study to investigate Trovagene s non invasive cancer monitoring technology using cell free DNA from urine samples
Trovagene collaborates with USC in a clinical study evaluating cancer monitoring technology Study to investigate Trovagene s non invasive cancer monitoring technology using cell free DNA from urine samples SAN DIEGO, CA September 6, 2013 Trovagene, Inc. (NASDAQ: TROV), a develo
Read more →CRDFTrovagene, Inc. Announces Second Quarter 2013 Earnings
Trovagene, Inc. Announces Second Quarter 2013 Earnings SAN DIEGO, CA August 14, 2013 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and the six months ended June 30, 2013. Second Quarter
Read more →CRDFTrovagene, Inc. Announces Closing of $15 Million Registered Direct Offering of Common Stock
Trovagene, Inc. Announces Closing of $15 Million Registered Direct Offering of Common Stock SAN DIEGO, CA July 31, 2013 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has closed a registered direct offering of $15 million
Read more →CRDFRainDrop System Unlocks Power of Trovagene's Urine-Based Mutation Detection Technology Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay SAN DIEGO, CA and BILLERICA, MA/PRNewswire/
RainDrop System Unlocks Power of Trovagene's Urine-Based Mutation Detection Technology Digital PCR system adoption helps create ultra-sensitive SAN DIEGO, CA and BILLERICA, MA/PRNewswire/ - July 29, 2013 - Trovagene, Inc. (NASDAQ: TROV) and RainDance Technologies announced to
Read more →CRDFTrovagene Announces Issuance of Broad MicroRNA Patent Patent covers methods of detecting cell-free microRNA in urine and blood
Trovagene Announces Issuance of Broad MicroRNA Patent Patent covers methods of detecting cell-free microRNA in urine and blood SAN DIEGO, July 24, 2013 /PRNewswire/ Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, announced the issuance of US patent 8,486
Read more →CRDFA better clinical pathway for cancer monitoring Antonius Schuh, Ph.D. | Chief Executive Officer July 2013 Forward-Looking Statements DISCLAIMER Statements in this presentation about the Company's expectations, applicatio
COMMERCIAL DEVELOPMENT UPDATE Illumina R&D agreement Goal POC to develop library for NGS (next generation sequencing) from cell-free DNA isolated from urine Strategic imperative to establish TrNAs on NGS NGS will become a platform standard in the industry TROV to gain significant
Read more →CRDFUrine-based Cancer Detection Technology Validated Trovagene develops ultra-sensitive cell-free DNA assay
Urine-based Cancer Detection Technology Validated Trovagene develops ultra-sensitive cell-free DNA assay SAN DIEGO, CA July 22, 2013 Trovagene, Inc. (NASDAQ: TROV) announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene
Read more →CRDFA better clinical pathway for cancer monitoring Antonius Schuh, Ph.D. | Chief Executive Officer June 2013 Forward-Looking Statements DISCLAIMER Statements in this presentation about the Company's expectations, applicatio
COMMERCIAL DEVELOPMENT UPDATE Illumina Agreement Goal POC to develop library for NGS (next generation sequencing) from cell-free DNA isolated from urine Strategic imperative to establish TrNAs on NGS NGS will become a platform standard in the industry TROV to gain significant dom
Read more →CRDFTrovagene, Inc. Announces First Quarter 2013 Earnings
Trovagene, Inc. Announces First Quarter 2013 Earnings SAN DIEGO, CA May 14, 2013 Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months ended March 31, 2013. First Quarter 2013 Financial Results
Read more →CRDFIntroduction to Trovagene, Inc. Antonius Schuh, Ph.D. Chief Executive Officer April 2013 Forward-Looking Statements DISCLAIMER Statements in this presentation about the Company's expectations, applications of its technol
Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia Issued European Patent for Detection of Pathogenic Infections Improved Liquidity and Access to Capital Completed Public Offering of $10 million and began trading on NASDAQ Added to the Russell Microcap and the
Read more →CRDFTrovagene, Inc. Announces Fourth Quarter and Year End 2012 Earnings
Trovagene, Inc. Announces Fourth Quarter and Year End 2012 Earnings SAN DIEGO, CA April 1, 2013 Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months and the year ended December 31, 2012. Fourt
Read more →CRDFTrovagene Launches Urine-Based HPV Test New, non-invasive molecular diagnostic test is easy, fast, and accurate
Trovagene Launches Urine-Based HPV Test New, non-invasive molecular diagnostic test is easy, fast, and accurate SAN DIEGO, March 27, 2013 /PRNewswire/ Trovagene, Inc. (NASDAQ: TROV), today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a mole
Read more →CRDFTrovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer SAN DIEGO, March 4, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today announced that Mark Erlander, Ph.D., has joined the company as chief scientific off
Read more →CRDFTrovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests SAN DIEGO, CA February 12, 2013 Trovagene, Inc. (NASDAQ: TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well and the
Read more →CRDFTrovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes
Trovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes SAN DIEGO, Jan. 3, 2013 /PRNewswire/ Trovagene, Inc. (Nasdaq: TR
Read more →CRDFTrovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center
Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center SAN DIEGO, Dec. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University an
Read more →CRDFTrovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia
Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia SAN DIEGO, Dec. 20, 2012 /PRNewswire/ Trovagene, Inc. (NASDAQ: TROV) today announced it has granted Genoptix, Inc. (a Novartis Group Company) a worldwide, non-exclusive license to incorpor
Read more →CRDFTrovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants SAN DIEGO, Nov. 21, 2012 Trovagene, Inc. (NASDAQ: TROV), a transrenal molecular diagnostic company, today announced the closing of a private placement consisti
Read more →CRDFTrovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE SAN DIEGO, CA November 14, 2012 PRNewswire Trovagene, Inc. (NASDAQ: TROV), a developer of tran
Read more →CRDFIntroduction to Trovagene, Inc. Antonius Schuh, PhD Chief Executive Officer November 2012 Forward-Looking Statements DISCLAIMER Statements in this presentation about the Company's expectations, applications of its techno
Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia Issued European Patent for Detection of Pathogenic Infections Improved Liquidity and Access to Capital Completed Public Offering and began trading on NASDAQ Added to the Russell Microcap Index Expansion of KRAS
Read more →CRDFIntroduction to Trovagene, Inc. Antonius Schuh, PhD Chief Executive Officer August 2012 Forward-Looking Statements DISCLAIMER Statements in this presentation about the Company's expectations, applications of its technolo
Internal estimate based on 10M HPV tests performed in 2007-2008, with 25-40% CAGR through 2011, as published in CAP Today, August 2008. 2. Castle et al. Clinical Human Papilloma Virus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow Up. J Clin Oncol, 30 J
Read more →CRDF: FOR RELEASE AT 6:00 AM EST, AUGUST 15, 2012 Trovagene, Inc., Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
Press Release: FOR RELEASE AT 6:00 AM EST, AUGUST 15, 2012 Trovagene, Inc., Announces Second Quarter and Year to Date Earnings, Provides Milestone Update COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE SAN DIEGO, August 15, 2012 /PRNews
Read more →CRDFTrovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
Trovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split SAN DIEGO, CA, May 30, 2012 Trovagene, Inc. (Nasdaq: TROV), a developer of trans-renal molecular diagnostics, announced the pricing of an underwrit
Read more →CRDFTrovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients SAN DIEGO, April 30, 2012 /PRNewswire/ Trovagene, Inc. (Pin
Read more →Competitive Position
How CRDF ranks across every disease it competes inCompetitive Position is a premium feature
See how CRDF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial